Key facts
- This page summarizes Amy Bachrodt's Form 4 filing for Lycia Therapeutics, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 26 Oct 2026, 18:58.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
Footnote F2
The options vest as to 1/4 of the total award on June 2, 2027, and an additional 1/48 of the total award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.